Weekly Fungal Diagnostics Update

Posted on by

Week Commencing 8 June 2026

Audience: Clinical microbiologists, infectious disease physicians, respiratory physicians, haematologists, transplant specialists, laboratory scientists and diagnostic mycology teams.

This week’s fungal diagnostics literature highlights a continuing transition from simple pathogen detection towards integrated clinical intelligence. The selected papers explore non-invasive diagnosis using blood metagenomic next-generation sequencing (mNGS), molecular identification of fungi from formalin-fixed paraffin-embedded (FFPE) tissue, artificial intelligence-assisted antifungal resistance prediction, targeted molecular diagnosis of pulmonary mucormycosis and the future of Aspergillus disease surveillance.

While none of the studies represents an immediate paradigm shift, collectively they demonstrate how diagnostic mycology is evolving. Sequencing technologies, molecular pathology, machine learning and surveillance science are increasingly complementing traditional culture, microscopy and histopathology. The challenge for laboratories will be determining where these technologies add genuine clinical value and how they can be integrated into routine diagnostic pathways.

Contents

Executive Summary

Five notable papers were identified from this week’s fungal diagnostics literature. Although the individual studies span very different areas of diagnostic mycology, they collectively illustrate a common theme: fungal diagnostics are increasingly moving beyond simple organism detection towards supporting clinical decision-making, treatment optimisation and public-health intelligence.

The first study, by Chen et al., evaluated peripheral blood metagenomic next-generation sequencing as a non-invasive adjunctive diagnostic tool for invasive pulmonary aspergillosis. This work reflects growing interest in reducing dependence on bronchoscopy and tissue sampling, particularly in high-risk immunocompromised patients.

The second paper, by Che et al., compared droplet digital PCR, internal transcribed spacer sequencing and metagenomic next-generation sequencing for fungal identification from formalin-fixed paraffin-embedded tissue. This study addresses a common and frustrating diagnostic problem encountered in pathology and mycology laboratories when fungal invasion is visible histologically but culture material is unavailable.

The third study, by Duroux et al., explored whether routinely generated MALDI-TOF mass spectrometry spectra can be analysed using machine-learning algorithms to predict antifungal resistance. While still early-stage, this work represents one of the most innovative developments in fungal diagnostics and hints at how artificial intelligence may transform laboratory workflows over the coming decade.

The fourth paper, by Prattes et al., examined the performance of bronchoalveolar lavage Mucorales PCR for diagnosing pulmonary mucormycosis. This remains one of the most difficult invasive fungal infections to diagnose rapidly and accurately, making targeted molecular diagnostics particularly attractive.

Finally, van Grootveld et al. presented a broader perspective on Aspergillus surveillance. Rather than focusing on individual diagnostic tests, the authors argue that surveillance systems should evolve from monitoring pathogens and resistance markers towards measuring disease burden, diagnostic delay, treatment patterns and patient outcomes.

Taken together, these studies suggest that the future of fungal diagnostics will be characterised by:

  • Less invasive diagnostic pathways.
  • Greater use of molecular technologies.
  • Integration of artificial intelligence into laboratory workflows.
  • Improved utilisation of archived tissue samples.
  • Closer linkage between diagnostics, surveillance and patient outcomes.

Of the five papers reviewed this week, the FFPE molecular diagnostics study is arguably the one with the greatest immediate practical relevance for specialist laboratories. The MALDI-TOF machine-learning paper is perhaps the most forward-looking, while the surveillance paper provides an important reminder that better diagnostics ultimately matter because they improve understanding of disease burden and patient outcomes.

1. Blood Metagenomic Next-Generation Sequencing for Invasive Pulmonary Aspergillosis

Chen J et al.
PMID: 41995327

Why This Study Matters

Invasive pulmonary aspergillosis (IPA) remains one of the most serious fungal infections encountered in modern medicine. Despite significant advances in antifungal therapy and diagnostic technology, diagnosis remains challenging, particularly in patients who are immunocompromised, critically ill or unable to undergo invasive procedures.

Current diagnostic pathways rely heavily on a combination of imaging, host-risk assessment and laboratory investigations. High-resolution computed tomography may reveal suggestive features such as nodules, cavitation or halo signs, while laboratory tests commonly include galactomannan, beta-D-glucan, Aspergillus PCR and fungal culture. However, many of these tests have important limitations.

Galactomannan performance varies according to patient population and antifungal exposure. Beta-D-glucan lacks specificity. Culture remains relatively insensitive and often takes several days to provide results. Most importantly, many of the strongest diagnostic tests require bronchoalveolar lavage (BAL) fluid obtained via bronchoscopy.

For patients with severe thrombocytopenia, respiratory instability, mechanical ventilation or significant comorbidity, bronchoscopy may be difficult, delayed or considered unsafe. Consequently, there has been increasing interest in whether blood-based molecular diagnostics could provide useful microbiological evidence without requiring respiratory sampling.

Study Aim

Chen and colleagues investigated whether peripheral blood metagenomic next-generation sequencing (mNGS) could support the diagnosis of invasive pulmonary aspergillosis.

Unlike targeted PCR assays, mNGS does not require the laboratory to decide in advance which organism is being sought. Instead, all nucleic acid present within a sample is sequenced and compared against large reference databases, allowing simultaneous detection of bacteria, fungi, viruses and parasites.

The attraction of this approach is obvious. A single blood sample could potentially provide broad-spectrum microbiological information without requiring invasive sampling.

Study Design

The study appears to have been a retrospective clinical evaluation of peripheral blood mNGS in patients suspected of having invasive pulmonary aspergillosis.

Patients underwent blood mNGS testing and results were compared with conventional diagnostic approaches and final clinical diagnosis. Comparator investigations likely included combinations of:

  • Serum galactomannan testing.
  • Beta-D-glucan testing.
  • Fungal culture.
  • Microscopy and histopathology where available.
  • Radiological findings.
  • Established invasive fungal disease criteria.

Although exact patient numbers require confirmation from the full publication, the study provides useful real-world data regarding the feasibility of blood-based fungal diagnostics.

Key Findings

The principal finding is that Aspergillus DNA can be detected in peripheral blood using metagenomic sequencing technology.

This is significant because Aspergillus is not primarily a bloodstream pathogen. Unlike Candida species, which commonly cause bloodstream infection, Aspergillus typically invades lung tissue and blood vessels locally rather than circulating freely within the bloodstream.

Consequently, many investigators have questioned whether blood-based molecular diagnostics would be sufficiently sensitive for routine use.

The study suggests that blood mNGS may provide clinically useful information in several scenarios:

  • When bronchoscopy is contraindicated.
  • When respiratory sampling is delayed.
  • When conventional fungal diagnostics are inconclusive.
  • When mixed infection is suspected.
  • When broad pathogen detection is clinically valuable.

One particularly attractive feature of mNGS is its ability to identify multiple organisms simultaneously. In immunocompromised patients, bacterial, fungal and viral infections frequently coexist, and a technology capable of detecting all of these from a single sample is appealing.

Strengths

The study addresses a clinically important unmet need. There is clear demand for less invasive approaches to diagnosing invasive fungal disease.

Additional strengths include:

  • Use of a minimally invasive sample type.
  • Potential applicability across multiple patient groups.
  • Broad-spectrum pathogen detection.
  • Culture-independent diagnosis.
  • Potential identification of mixed infections.

Importantly, the study evaluates a technology that could potentially fit into existing clinical workflows with relatively little burden on patients.

Limitations

Several limitations deserve consideration.

First, the biological behaviour of Aspergillus creates inherent challenges for blood-based diagnostics. Fungal DNA may be present in blood only intermittently and at low concentrations. Detection may depend heavily on fungal burden, disease stage, antifungal treatment and host immune status.

Second, interpretation remains difficult. Detection of Aspergillus DNA does not necessarily prove invasive disease. Potential sources of signal include contamination, transient DNA release and environmental exposure.

Third, mNGS remains relatively expensive compared with established fungal diagnostics. Laboratory infrastructure, bioinformatic support and standardisation remain substantial barriers to widespread implementation.

Finally, most currently available studies are retrospective and involve relatively small patient populations. Prospective multicentre validation remains essential.

Clinical Implications

For clinicians, the study reinforces the possibility that blood mNGS may become a useful adjunctive investigation in diagnostically difficult cases.

The most likely near-term role is not as a replacement for bronchoscopy, galactomannan or Aspergillus PCR, but as an additional source of evidence when conventional investigations are unavailable or inconclusive.

In specialist centres, blood mNGS may prove particularly valuable for:

  • Patients unable to undergo bronchoscopy.
  • Breakthrough fungal infections.
  • Complex mixed infections.
  • Critically ill patients requiring rapid microbiological information.

Editorial Perspective

The importance of this study lies less in its immediate diagnostic performance and more in what it represents. Across infectious diseases, there is a clear trend towards less invasive diagnostics. Similar developments are occurring in oncology, transplantation medicine and infectious diseases more broadly.

The question is no longer whether fungal diagnostics can be performed on blood samples, but whether they can be performed reliably enough to influence clinical decision-making.

The answer remains uncertain. However, studies such as this suggest that blood-based fungal diagnostics are gradually moving from theoretical possibility towards practical clinical reality.

If future studies demonstrate robust performance, standardised reporting and clear clinical utility, blood mNGS could become an important component of future invasive fungal disease pathways.

Overall assessment: Promising adjunctive technology with substantial future potential, but currently best viewed as a supplementary diagnostic tool rather than a stand-alone test.

2. FFPE Tissue Identification: ddPCR vs ITS Sequencing vs mNGS

Che J et al.
PMID: 42133463

Why This Study Matters

One of the most common frustrations in diagnostic mycology occurs when histopathology clearly demonstrates fungal invasion but the causative organism cannot be identified with confidence.

Pathologists may report septate hyphae, broad non-septate hyphae, yeast-like organisms or fungal elements consistent with mould infection, yet morphology alone is often insufficient to distinguish between clinically important pathogens. This distinction matters because treatment decisions increasingly depend on accurate identification.

For example, distinguishing Aspergillus species from Mucorales can fundamentally alter antifungal management. Similarly, identification of Fusarium, Lomentospora, Scedosporium, dematiaceous fungi or endemic fungi may have major implications for treatment selection, prognosis and infection control.

Unfortunately, in many cases fresh tissue suitable for culture was never submitted. The only material available is formalin-fixed paraffin-embedded (FFPE) tissue stored within pathology archives.

Historically, FFPE tissue was viewed as problematic for molecular testing because formalin fixation fragments and chemically modifies DNA. However, advances in molecular diagnostics have increasingly challenged this assumption.

This study addresses a highly practical question faced by specialist laboratories: which molecular approach performs best when fungal identification must be obtained from FFPE tissue?

Study Aim

Che and colleagues compared three distinct molecular approaches for fungal identification from FFPE tissue:

  • Droplet Digital Polymerase Chain Reaction (ddPCR)
  • Internal Transcribed Spacer (ITS) Sequencing
  • Metagenomic Next-Generation Sequencing (mNGS)

These technologies represent three different diagnostic philosophies.

ddPCR is highly targeted and sensitive. ITS sequencing provides broad fungal identification using a recognised fungal barcode region. mNGS offers untargeted sequencing capable of detecting virtually any fungal DNA present within a specimen.

The study therefore provides an opportunity to compare targeted, broad-range and unbiased sequencing approaches using one of the most challenging specimen types encountered in routine practice.

Understanding the Three Approaches

Droplet Digital PCR (ddPCR)

ddPCR divides a sample into thousands of microscopic droplets, allowing individual PCR reactions to occur within each droplet. This technology enables extremely sensitive detection of low-abundance targets.

For fungal diagnostics, ddPCR is particularly attractive when clinicians already suspect a specific pathogen group and require highly sensitive confirmation.

However, ddPCR can only detect organisms included within the assay design. Unexpected pathogens will not be identified.

ITS Sequencing

The Internal Transcribed Spacer (ITS) region is often referred to as the fungal equivalent of a barcode. Sequencing this region allows comparison against reference databases and can provide broad fungal identification.

ITS sequencing has become familiar to many reference mycology laboratories and remains one of the most widely used approaches for fungal species identification.

The challenge with FFPE tissue is that DNA fragmentation may prevent successful amplification of the ITS target region.

Metagenomic Next-Generation Sequencing

Unlike ddPCR or ITS sequencing, mNGS does not require prior assumptions regarding the pathogen present.

All DNA within a sample is sequenced, allowing identification of fungi, bacteria, viruses and other organisms simultaneously.

This broad detection capability makes mNGS attractive for unusual infections, mixed infections or diagnostically challenging cases. However, it also increases complexity, cost and interpretive burden.

Key Findings

The study demonstrated that all three approaches can provide clinically useful information from FFPE tissue, but no single method was clearly superior in every circumstance.

Instead, the results suggest that each technology occupies a different niche within the diagnostic pathway.

ddPCR appears particularly useful when:

  • A specific fungal pathogen is suspected.
  • DNA quantity is limited.
  • Maximum analytical sensitivity is required.
  • Rapid targeted answers are needed.

ITS sequencing remains valuable when:

  • Broader fungal identification is required.
  • DNA quality is adequate.
  • Species-level identification is needed.
  • Reference laboratory support is available.

mNGS may be most valuable when:

  • The pathogen is unknown.
  • Mixed infection is suspected.
  • Conventional diagnostics have failed.
  • Rare or unexpected fungi are possible.

Importantly, the study reinforces that meaningful fungal identification can often still be recovered from tissue samples that would previously have been considered diagnostically exhausted.

Strengths

This is arguably the strongest practical laboratory paper reviewed this week.

Key strengths include:

  • Direct comparison of multiple molecular approaches.
  • Focus on a common real-world diagnostic problem.
  • Relevance to invasive fungal disease management.
  • Evaluation of clinically important specimen types.
  • Potential implications for antifungal stewardship.

The study also avoids the common trap of presenting a single technology as the solution to all diagnostic challenges. Instead, it recognises that different methods may be appropriate in different circumstances.

Limitations

FFPE tissue remains an inherently difficult specimen type.

Challenges include:

  • DNA fragmentation.
  • Chemical modification of nucleic acids.
  • Variable fixation practices.
  • Low fungal burden.
  • Environmental contamination.
  • Mixed microbial signals.

Another important limitation is that histopathology itself rarely provides a perfect species-level reference standard. Evaluating molecular performance therefore becomes more difficult than in conventional microbiological studies.

Interpretation also remains challenging. Detection of fungal DNA does not automatically confirm that the identified organism was responsible for tissue invasion.

Clinical Implications

The findings support increasing integration of molecular testing into pathology workflows.

In many centres, future diagnostic pathways may look something like:

  1. Histopathology confirms fungal invasion.
  2. Targeted ddPCR performed when specific pathogens are suspected.
  3. ITS sequencing used for broader fungal identification.
  4. mNGS reserved for unresolved, complex or unusual cases.

This tiered strategy may offer the best balance between sensitivity, breadth of detection, cost and clinical utility.

For reference laboratories, the study also highlights the growing importance of collaboration between pathology, microbiology, molecular diagnostics and infectious disease teams.

Editorial Perspective

Among all five papers reviewed this week, this is arguably the one most likely to influence routine laboratory practice in the near future.

Every specialist mycology laboratory encounters cases where fungal invasion is obvious histologically but definitive identification remains elusive. Historically, those cases often remained unresolved.

Studies such as this demonstrate that archived tissue can continue to provide clinically useful information long after conventional diagnostic opportunities have been lost.

Rather than replacing histopathology, these molecular approaches enhance it. The future is likely to involve increasingly integrated pathology-molecular workflows where tissue invasion is demonstrated morphologically and organism identification is provided by molecular methods.

For centres managing invasive fungal disease, that represents a meaningful and immediately practical advance.

Overall assessment: The most immediately applicable study this week. Strong practical relevance for specialist laboratories and an excellent example of how molecular diagnostics can complement traditional pathology.

3. Early Antifungal Resistance Prediction Using MALDI-TOF Mass Spectrometry and Machine Learning

Duroux D et al.
PMID: 42230876

Why This Study Matters

Over the past two decades, MALDI-TOF mass spectrometry has transformed clinical microbiology. Organism identification that once took days can now often be achieved within minutes. Today, MALDI-TOF instruments are routine equipment in microbiology laboratories across Europe, North America and many other regions.

However, despite its remarkable success, MALDI-TOF has traditionally been viewed primarily as an identification tool. Once an organism is identified, separate testing is usually required to determine antimicrobial or antifungal susceptibility.

This separation creates an important delay. Clinicians may know the identity of an organism but still have to wait days for susceptibility results before optimal therapy can be selected.

At the same time, antifungal resistance continues to emerge as a major challenge. Azole-resistant Aspergillus fumigatus, multidrug-resistant Candida auris, resistant Candida glabrata and other difficult fungal pathogens are becoming increasingly important worldwide.

The question explored by Duroux and colleagues is therefore both simple and potentially transformative:

Can information already present within MALDI-TOF spectra be used to predict antifungal resistance before conventional susceptibility testing is completed?

Study Aim

Duroux et al. investigated whether machine-learning algorithms could analyse routinely generated MALDI-TOF mass spectrometry spectra and identify patterns associated with antifungal resistance.

Rather than developing a completely new diagnostic platform, the study seeks to extract additional clinical value from technology that many laboratories already possess.

This concept is increasingly referred to as augmented diagnostics — using artificial intelligence to derive new information from existing laboratory data.

Study Design

The investigators used MALDI-TOF spectra from fungal isolates alongside known antifungal susceptibility results.

Machine-learning models were then trained to recognise spectral patterns associated with resistant and susceptible phenotypes.

Multiple computational approaches were evaluated, including:

  • Support Vector Machines (SVM).
  • Multilayer Perceptron Neural Networks (MLP).
  • Other machine-learning classification models.

Performance was assessed using recognised machine-learning metrics including:

  • Balanced accuracy.
  • Precision-recall analysis.
  • Matthews correlation coefficient.
  • Classification performance measures.

Although the exact isolate numbers require confirmation from the full publication, the study represents one of the more sophisticated applications of artificial intelligence currently appearing within diagnostic mycology.

Key Findings

The most important finding is that antifungal resistance appears to leave detectable signatures within MALDI-TOF spectra.

These signatures may not be recognisable to human observers, but machine-learning algorithms were able to identify patterns associated with resistant phenotypes.

The study found that:

  • MALDI-TOF spectra contain information beyond species identification.
  • Machine-learning models can exploit this information.
  • Multilayer perceptron neural networks and support vector machines performed particularly well.
  • Resistance prediction may be possible before conventional susceptibility testing is complete.

Perhaps the most exciting aspect is that no new specimen type is required. The information is derived from spectra already being generated during routine laboratory workflows.

Why This Could Be Important

Currently, fungal diagnostics typically follow a sequence:

  1. Culture growth.
  2. Species identification.
  3. Susceptibility testing.
  4. Clinical interpretation.

Even in efficient laboratories, susceptibility testing can add significant delay.

If machine-learning analysis of MALDI-TOF spectra can reliably predict resistance, clinicians might receive an early warning that a resistant organism is present while formal susceptibility testing continues in parallel.

Potential applications include:

  • Earlier escalation of therapy.
  • Improved antifungal stewardship.
  • Rapid identification of high-risk isolates.
  • Enhanced surveillance of resistance trends.
  • Prioritisation of isolates for confirmatory testing.

This could be particularly valuable for pathogens where resistance has major treatment implications.

Potential Relevance to Aspergillus

For readers working in respiratory medicine and fungal disease, perhaps the most interesting future application concerns azole-resistant Aspergillus fumigatus.

Environmental azole resistance continues to attract significant attention internationally. Current approaches often require culture followed by susceptibility testing or molecular detection of resistance mutations.

A future workflow in which MALDI-TOF identification simultaneously generates an estimate of resistance risk would be highly attractive.

Although this remains speculative, studies such as this provide the first evidence that such a future may be technically feasible.

Strengths

The study has several notable strengths:

  • Uses technology already present in many laboratories.
  • Addresses an important clinical problem.
  • Explores innovative use of existing diagnostic data.
  • Evaluates multiple machine-learning approaches.
  • Demonstrates proof-of-concept feasibility.

Unlike many emerging diagnostic technologies, implementation would not necessarily require entirely new instrumentation.

Limitations

The study also faces substantial challenges.

Perhaps the biggest concern is generalisability.

Machine-learning models often perform extremely well on the data used to train them but less well when applied elsewhere. Spectral acquisition methods, culture conditions, instrument calibration and local workflows may differ between laboratories.

Other important limitations include:

  • Potential overfitting.
  • Limited external validation.
  • Variable performance across fungal species.
  • Potential differences between antifungal drug classes.
  • Limited interpretability of some machine-learning models.

Regulatory approval and clinical implementation would require extensive multicentre validation.

Clinical Implications

At present, this technology should not be viewed as a replacement for conventional antifungal susceptibility testing.

However, it may eventually function as:

  • An early warning system.
  • A triage tool.
  • A resistance surveillance platform.
  • A decision-support aid for clinicians.

The greatest short-term value may be in identifying isolates that warrant urgent confirmatory testing.

Editorial Perspective

This is probably the most innovative paper reviewed this week.

Unlike the FFPE study, which addresses an immediate practical problem, the Duroux paper provides a glimpse of where fungal diagnostics may be heading over the next decade.

Historically, diagnostic tests have been designed to answer specific questions. Artificial intelligence changes that relationship. Increasingly, the question becomes:

“What additional information is already hidden within data we routinely generate?”

MALDI-TOF transformed microbiology by accelerating organism identification. If future studies validate resistance prediction from the same spectra, the impact could be equally significant.

Whether that future arrives in five years or fifteen remains uncertain, but studies such as this suggest it is no longer science fiction.

Overall assessment: The most forward-looking study this week. Limited immediate clinical impact, but potentially profound long-term implications for diagnostic mycology and antifungal stewardship.

4. Mucorales PCR in Bronchoalveolar Lavage Samples for the Diagnosis of Pulmonary Mucormycosis

Prattes J et al.
PMID: 41610953

Why This Study Matters

Pulmonary mucormycosis remains one of the most difficult invasive fungal infections to diagnose rapidly and accurately. Although considerably less common than invasive pulmonary aspergillosis, mucormycosis carries a high mortality rate and often requires fundamentally different management.

This distinction is critically important. Antifungal agents commonly used for invasive aspergillosis, particularly voriconazole, do not provide reliable activity against Mucorales. Consequently, diagnostic delay can lead to inappropriate treatment and poorer clinical outcomes.

Unfortunately, diagnosis is notoriously challenging.

Radiological findings often overlap with those seen in invasive aspergillosis. Culture is frequently negative. Histopathological confirmation may require invasive procedures that are not always possible in critically ill, neutropenic or thrombocytopenic patients.

These challenges have led to growing interest in molecular diagnostics capable of detecting Mucorales directly from respiratory samples.

Study Aim

Prattes and colleagues evaluated the clinical performance of bronchoalveolar lavage (BAL) Mucorales polymerase chain reaction (PCR) testing in patients investigated for pulmonary mucormycosis.

The goal was to determine whether targeted molecular testing could improve diagnostic confidence in situations where conventional methods are limited.

Background: Why Pulmonary Mucormycosis Is Difficult to Diagnose

Several factors contribute to the diagnostic challenge.

First, Mucorales organisms are notoriously difficult to culture. Even when tissue invasion is present, respiratory cultures may remain negative.

Second, patients at highest risk often have significant haematological disease, severe immunosuppression or profound thrombocytopenia. These factors may limit the feasibility of lung biopsy.

Third, radiological findings are not entirely specific. Features such as nodules, consolidation, cavitation and the reverse halo sign may raise suspicion, but cannot definitively establish the diagnosis.

As a result, clinicians are frequently forced to make treatment decisions in the setting of considerable diagnostic uncertainty.

Study Design

The study assessed Mucorales PCR performed on BAL fluid from patients investigated for invasive pulmonary fungal infection.

Results were compared with final clinical classification and conventional diagnostic approaches including:

  • Radiology.
  • Fungal culture.
  • Microscopy.
  • Histopathology where available.
  • Clinical risk factors.
  • Overall multidisciplinary assessment.

The patient population was particularly relevant because it included individuals at high risk of invasive fungal disease, including those with haematological malignancies and severe immunosuppression.

Key Findings

The study supports BAL Mucorales PCR as a useful adjunctive diagnostic tool, although performance was not sufficient for use as a stand-alone test.

Several important observations emerged:

  • Positive BAL PCR results provided useful microbiological evidence supporting pulmonary mucormycosis.
  • PCR identified some cases in which culture remained negative.
  • Positive molecular findings may be particularly valuable when biopsy is not possible.
  • Sensitivity appeared incomplete, meaning some proven cases remained PCR-negative.

One of the most clinically important observations was that BAL PCR provided supportive evidence in situations where invasive tissue confirmation could not be obtained because of thrombocytopenia or clinical instability.

This reflects a common real-world problem faced by clinicians managing high-risk patients.

Positive Results Versus Negative Results

A particularly useful way of interpreting the findings is to consider the implications of positive and negative results separately.

When PCR Is Positive

A positive BAL Mucorales PCR result may provide important microbiological support for the diagnosis of pulmonary mucormycosis.

When combined with appropriate host-risk factors and compatible radiology, a positive result can significantly strengthen clinical suspicion.

In some patients, this may help justify early initiation or escalation of antifungal therapy while further investigations continue.

When PCR Is Negative

The situation is very different for negative results.

Because sensitivity appears incomplete, a negative BAL PCR cannot reliably exclude pulmonary mucormycosis.

This distinction is important. Clinicians must avoid interpreting a negative result as evidence that disease is absent when clinical suspicion remains high.

The study therefore supports use of BAL PCR as a “rule-in” aid rather than a “rule-out” test.

Strengths

The study addresses an area of genuine clinical need.

Important strengths include:

  • Focus on a life-threatening fungal infection.
  • Use of a clinically relevant respiratory specimen.
  • Evaluation in high-risk patient populations.
  • Direct relevance to real-world diagnostic pathways.
  • Potential utility when tissue diagnosis is not feasible.

The work also highlights the increasing role of molecular diagnostics in invasive mould infections.

Limitations

Several limitations should be acknowledged.

Pulmonary mucormycosis remains relatively uncommon, making large prospective studies difficult.

Other challenges include:

  • Small numbers of proven cases.
  • Potential selection bias.
  • Variable fungal burden within respiratory samples.
  • Prior antifungal therapy affecting detection.
  • Differences between PCR platforms and laboratories.
  • Lack of universal assay standardisation.

Importantly, molecular positivity must always be interpreted alongside clinical context and radiological findings.

A PCR result alone cannot determine whether a detected organism is causing disease.

Clinical Implications

For specialist centres, the study supports incorporation of Mucorales PCR into broader invasive fungal disease diagnostic pathways.

The greatest value is likely to be seen in:

  • Haematology patients.
  • Stem cell transplant recipients.
  • Solid organ transplant recipients.
  • Patients with prolonged neutropenia.
  • Individuals unable to undergo biopsy.

Mucorales PCR should be considered alongside:

  • Aspergillus PCR.
  • Galactomannan testing.
  • Fungal culture.
  • Radiology.
  • Histopathology.
  • Multidisciplinary review.

This integrated approach remains essential for accurate diagnosis.

Editorial Perspective

Unlike the highly innovative MALDI-TOF machine-learning paper, this study addresses an immediate clinical problem encountered by specialist centres every week.

Pulmonary mucormycosis remains one of the few invasive fungal diseases where diagnostic uncertainty can have particularly serious consequences because treatment differs so markedly from invasive aspergillosis.

The study’s most important message is not that PCR solves the diagnostic problem, but that it provides another valuable piece of evidence within a broader diagnostic puzzle.

That theme appears repeatedly throughout this week’s literature. New molecular diagnostics rarely replace existing methods; instead, they add information that strengthens clinical decision-making.

For pulmonary mucormycosis, even modest improvements in diagnostic confidence may translate into earlier recognition and more appropriate therapy.

Overall assessment: A clinically useful study with immediate relevance for specialist fungal centres. BAL Mucorales PCR appears most valuable as an adjunctive “rule-in” tool rather than a definitive diagnostic or exclusion test.

Why Distinguishing Mucormycosis from Aspergillosis Matters

One of the most important clinical challenges in invasive mould disease is differentiating pulmonary mucormycosis from invasive pulmonary aspergillosis. The two conditions may present with remarkably similar radiological findings, overlapping clinical symptoms and comparable host-risk factors.

However, treatment implications are substantial. Voriconazole remains a cornerstone of invasive aspergillosis management but has no reliable activity against Mucorales. Conversely, therapies active against Mucorales may expose patients to additional toxicity or cost if used unnecessarily.

The consequence is that diagnostic uncertainty may directly influence treatment selection. Clinicians are frequently forced to balance the risks of delayed treatment against the risks of broad-spectrum antifungal therapy.

Molecular diagnostics such as BAL Mucorales PCR are therefore valuable not only because they detect pathogens, but because they may help narrow differential diagnoses and support more targeted therapeutic decisions.

This role is likely to become increasingly important as molecular respiratory fungal panels continue to expand and become integrated into routine practice.

Future Directions

The future diagnostic pathway for invasive mould disease is unlikely to rely on a single test. Instead, emerging evidence suggests that clinicians will increasingly combine radiology, fungal biomarkers, targeted PCR assays, sequencing technologies and host-risk assessment to build diagnostic confidence.

Within this framework, BAL Mucorales PCR may become an important component of specialist mould diagnostics, particularly when used alongside Aspergillus PCR and galactomannan testing.

The long-term challenge will be determining how these multiple sources of information can be integrated into validated diagnostic algorithms that improve outcomes without creating unnecessary complexity.

5. From Aspergillus Pathogen Surveillance to Disease Surveillance

van Grootveld R et al.
PMID: 41862136

Why This Paper Matters

Unlike the other papers reviewed this week, this is not primarily a study of a diagnostic technology. Instead, it addresses a broader question:

Are we measuring the right things when we monitor Aspergillus-related disease?

For many years, Aspergillus surveillance has focused on the organism itself. Surveillance programmes have monitored environmental Aspergillus fumigatus isolates, antifungal resistance mechanisms, resistance mutations such as those involving the cyp51A gene and changing susceptibility patterns.

These efforts have generated important information, particularly regarding the emergence of environmental azole resistance.

However, pathogen surveillance alone cannot answer many of the questions that matter most to patients, clinicians and healthcare systems.

For example:

  • How many people develop aspergillosis each year?
  • How many remain undiagnosed?
  • How long does diagnosis take?
  • Which patient groups experience the greatest delays?
  • How does antifungal resistance affect outcomes?
  • Where are specialist diagnostic services unavailable?
  • What is the true healthcare burden of aspergillosis?

These are fundamentally disease-surveillance questions rather than pathogen-surveillance questions.

Study Aim

van Grootveld and colleagues argue that Aspergillus surveillance systems should evolve from measuring organisms and resistance markers towards measuring disease burden, diagnostic activity, treatment patterns and patient outcomes.

The paper proposes a broader surveillance framework in which laboratory findings are linked directly to clinical disease and healthcare impact.

Current Limitations of Aspergillus Surveillance

Current surveillance systems frequently focus on what laboratories can easily measure:

  • Environmental Aspergillus isolates.
  • Clinical Aspergillus isolates.
  • Resistance mutations.
  • Antifungal susceptibility profiles.
  • Laboratory positivity rates.

These metrics are undoubtedly valuable. However, they provide only part of the picture.

A country may know its prevalence of azole-resistant Aspergillus fumigatus yet still have little understanding of:

  • The true incidence of chronic pulmonary aspergillosis.
  • Rates of allergic bronchopulmonary aspergillosis.
  • Diagnostic delays.
  • Referral patterns.
  • Access to specialist expertise.
  • Treatment outcomes.

The authors argue that surveillance systems should increasingly focus on these clinically meaningful endpoints.

The Shift from Pathogens to Patients

A key message of the paper is that detecting Aspergillus is not the same as measuring Aspergillus disease.

Aspergillus species are ubiquitous environmental organisms. Millions of people inhale Aspergillus spores every day without developing disease.

Consequently, surveillance systems that simply measure environmental prevalence or laboratory detection rates may overestimate or underestimate the true clinical impact of Aspergillus.

The authors propose that surveillance should increasingly incorporate:

  • Disease incidence.
  • Disease prevalence.
  • Diagnostic pathways.
  • Treatment patterns.
  • Patient outcomes.
  • Healthcare utilisation.
  • Mortality.
  • Quality-of-life measures.

This represents a significant conceptual shift from organism-centred surveillance towards patient-centred surveillance.

Implications for Diagnostic Laboratories

The paper has important implications for clinical microbiology and mycology services.

Historically, laboratories have primarily been responsible for generating diagnostic results. Increasingly, however, laboratories may become key contributors to disease-surveillance systems.

Future surveillance frameworks may require routine capture of:

  • Which patients are being tested.
  • Which tests are used.
  • Species identification.
  • Antifungal susceptibility results.
  • Molecular resistance markers.
  • Diagnostic turnaround times.
  • Diagnostic positivity rates.

This would place fungal diagnostics at the centre of surveillance infrastructure rather than treating laboratories simply as data providers.

Relevance to Chronic Pulmonary Aspergillosis

One of the most interesting aspects of the paper is its relevance to chronic pulmonary aspergillosis (CPA).

Unlike invasive aspergillosis, CPA often suffers from prolonged diagnostic delay. Many patients experience symptoms for months or years before diagnosis.

Current surveillance systems frequently struggle to capture:

  • When symptoms began.
  • When diagnosis occurred.
  • Which investigations were performed.
  • Whether referral pathways functioned effectively.
  • How outcomes varied geographically.

The authors’ proposed framework would allow much better understanding of these issues.

For specialist centres, this could help identify inequities in access to diagnosis and treatment.

The Importance of Diagnostic Delay

Perhaps the most overlooked aspect of fungal disease surveillance is diagnostic delay.

Traditional surveillance systems often count diagnosed cases but rarely measure how long it took patients to receive that diagnosis.

Yet diagnostic delay may have profound consequences:

  • Disease progression.
  • Increased healthcare utilisation.
  • Reduced quality of life.
  • Greater treatment complexity.
  • Higher healthcare costs.

The paper argues that future surveillance systems should capture these dimensions alongside conventional laboratory data.

Strengths

The paper’s greatest strength is its strategic perspective.

Rather than focusing on a single diagnostic technology, it considers how diagnostics, epidemiology, clinical services and public health interact.

Additional strengths include:

  • Recognition of current surveillance gaps.
  • Strong patient-centred focus.
  • Relevance across multiple forms of aspergillosis.
  • Alignment with One Health principles.
  • Emphasis on outcomes rather than organisms alone.

Limitations

This is a conceptual and policy-focused paper rather than a primary research study.

Consequently, it does not directly demonstrate improved outcomes.

Implementation challenges remain substantial and include:

  • Data governance.
  • Interoperability between systems.
  • Case definition standardisation.
  • Coding accuracy.
  • Funding requirements.
  • National coordination.

Perhaps most importantly, disease surveillance remains dependent upon diagnosis. Patients who are never tested or never referred remain invisible within surveillance systems.

Why This Matters for National Aspergillosis Services

The concepts discussed in this paper are particularly relevant to specialist fungal centres.

Many centres are increasingly interested not simply in counting cases but understanding:

  • Where patients originate.
  • How they enter referral pathways.
  • Which populations are underserved.
  • Where diagnostic delays occur.
  • How outcomes vary geographically.

These questions are essential for improving equity of access, service planning and healthcare resource allocation.

In many respects, the paper provides a framework for the next phase of fungal disease surveillance.

Editorial Perspective

Although this paper contains no new diagnostic technology, it may ultimately prove one of the most important papers reviewed this week.

The other studies focus on generating better diagnostic information. This paper asks a different question:

Once we have better diagnostic information, how should we use it?

That question is increasingly important.

Advances in sequencing, molecular diagnostics and artificial intelligence will generate enormous amounts of data. The challenge will be ensuring that these data improve patient outcomes, reduce diagnostic delay and support healthcare planning.

The future of Aspergillus surveillance is therefore likely to depend as much on data integration and clinical interpretation as on laboratory innovation.

For diagnostic mycology, that represents an important evolution from measuring organisms towards understanding disease.

Overall assessment: The most strategically important paper reviewed this week. Less about diagnostic technology and more about how diagnostics should support patient care, healthcare planning and public-health decision-making.

Emerging Themes This Week

Several common themes emerge from this week’s literature.

First, there is a clear movement towards less invasive diagnosis. Both blood metagenomic next-generation sequencing and bronchoalveolar lavage molecular testing seek to reduce reliance on surgical biopsy and other invasive procedures, particularly in vulnerable patient populations.

Second, laboratories are increasingly extracting additional information from specimens and data already available. The FFPE tissue study demonstrates how archived pathological material can yield valuable species-level information, while the MALDI-TOF machine-learning study suggests that routinely generated spectral data may contain clinically relevant information extending beyond species identification.

Third, molecular diagnostics continue to evolve from simple pathogen detection towards supporting clinical decision-making. Rather than asking only whether a pathogen is present, newer approaches increasingly seek to identify resistance patterns, predict treatment response and guide patient management.

Finally, the surveillance framework proposed by van Grootveld and colleagues highlights a broader shift from pathogen-centred thinking towards disease-centred thinking. Future fungal surveillance systems are likely to depend increasingly on integration of laboratory, clinical and outcome data.

Editor’s Summary

This week’s literature highlights a continuing evolution in fungal diagnostics. The most immediately applicable study was the comparison of molecular methods for fungal identification from FFPE tissue, addressing a common problem encountered in routine pathology and mycology practice. The most innovative paper explored machine-learning analysis of MALDI-TOF spectra for antifungal resistance prediction, providing a glimpse of future diagnostic workflows.

Collectively, these studies demonstrate that fungal diagnostics are increasingly focused not only on identifying pathogens but also on supporting clinical decision-making, antifungal stewardship and healthcare planning. As new technologies emerge, their greatest value will likely come through integration with existing diagnostic pathways rather than replacement of established methods.

What This Means for Clinical Mycology Services

Taken together, the studies reviewed this week illustrate several important trends that are likely to influence the future direction of clinical mycology services.

First, molecular diagnostics continue to expand beyond their traditional role as pathogen-detection tools. Blood metagenomic next-generation sequencing, targeted respiratory PCR assays and molecular testing of archived tissue all seek to address areas where conventional diagnostics may be limited. However, these technologies are not replacing existing approaches. Instead, they are increasingly being integrated alongside imaging, histopathology, culture and fungal biomarker testing to provide a more complete diagnostic picture.

Second, pathology and microbiology services are becoming more closely linked. The FFPE tissue study highlights the growing importance of molecular pathology in invasive fungal disease. Future diagnostic pathways are likely to involve closer collaboration between pathologists, molecular scientists, microbiologists and infectious disease specialists, particularly in culture-negative cases.

Third, artificial intelligence is beginning to move from theoretical discussion into practical laboratory evaluation. Although machine-learning analysis of MALDI-TOF spectra remains at an early stage, it demonstrates how existing laboratory data may be used to generate clinically relevant information beyond species identification. Similar approaches are likely to appear increasingly within diagnostic microbiology over the coming years.

Fourth, specialist centres should anticipate continued growth in sequencing-based diagnostics. Whether applied to blood, respiratory samples or archived tissue, sequencing technologies are becoming more accessible and increasingly relevant to difficult diagnostic cases. The challenge will be determining where these technologies provide sufficient additional value to justify their complexity and cost.

Finally, the surveillance paper serves as an important reminder that diagnostics do not exist in isolation. Improved diagnostic capability should ultimately translate into better understanding of disease burden, reduced diagnostic delay, more equitable access to specialist services and improved patient outcomes. Future fungal surveillance systems are likely to depend on closer integration between laboratory data, clinical information and outcome measures.

For clinical mycology services, the overall message is clear: the future lies not in any single diagnostic technology, but in combining molecular diagnostics, conventional microbiology, pathology, bioinformatics and clinical expertise into integrated diagnostic pathways that support patient-centred care.

References

  1. Chen J et al. Invasive Pulmonary Aspergillosis Diagnosis via Peripheral Blood Metagenomic Next-Generation Sequencing. PMID: 41995327.
  2. Che J et al. Comparison of droplet digital PCR, ITS sequencing and metagenomic next-generation sequencing for fungal identification from FFPE tissue. PMID: 42133463.
  3. Duroux D et al. Early antifungal resistance prediction based on MALDI-TOF mass spectrometry and machine learning. PMID: 42230876.
  4. Prattes J et al. Clinical performance of bronchoalveolar lavage Mucorales PCR for pulmonary mucormycosis diagnosis. PMID: 41610953.
  5. van Grootveld R et al. From Aspergillus pathogen surveillance to disease surveillance. PMID: 41862136.